ESMO Annual Congress

Avelumab frontline maintenance benefit sustained across subgroups in bladder cancer

September 29, 2020

An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.